Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Trial of Wellbutrin for Crohn's Disease

This study has been completed.
Information provided by (Responsible Party):
Altschuler, Eric, M.D. Identifier:
First received: August 2, 2005
Last updated: January 19, 2012
Last verified: January 2012

The investigators are testing the hypothesis that Wellbutrin (bupropion) can give a clinical remission in Crohn's disease.

Condition Intervention Phase
Crohn Disease
Drug: Wellbutrin (bupropion)
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized Controlled Trial of Wellbutrin for Crohn's Disease

Resource links provided by NLM:

Further study details as provided by Altschuler, Eric, M.D.:

Primary Outcome Measures:
  • Number of patients with Crohn's disease activity index (CDAI) < 150 at the end of twelve weeks [ Time Frame: 0, 2, 4, 8, 12 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Number of patients with CDAI drop of at least 70 points at the end of twelve weeks [ Time Frame: 0, 12 weeks ] [ Designated as safety issue: No ]
  • Time course of CDAI [ Time Frame: 0, 2, 4, 8, 12 weeks ] [ Designated as safety issue: No ]
  • Effect of drug and/or placebo on tumor necrosis factor-alpha (TNF) levels [ Time Frame: 0, 12 weeks ] [ Designated as safety issue: No ]

Enrollment: 1
Study Start Date: May 2005
Study Completion Date: March 2006
Primary Completion Date: March 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Sugar pill
Placebo (sugar) pill with identical look to bupropion
Drug: Wellbutrin (bupropion)
bupropion 150mg-300mg daily
Other Name: Wellbutrin, bupropion
Experimental: buproprion
bupropion pill
Drug: Wellbutrin (bupropion)
bupropion 150mg-300mg daily
Other Name: Wellbutrin, bupropion

Detailed Description:

Wellbutrin (bupropion) is approved for use as an antidepressant. There have been some cases in which people on Wellbutrin had significant improvement clinically in their Crohn's disease. In this trial, the hypothesis that Wellbutrin can induce clinical remission in Crohn's disease will be tested. The investigators will also be looking to see if Wellbutrin can lower levels of the inflammatory cytokine tumor necrosis factor-alpha (TNF).


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Moderate to severe Crohn's disease with 220 < CDAI < 400.
  • All patients in the study must have not had any anti-TNF antibodies for at least eight weeks.

Exclusion Criteria:

  • Patients will be excluded from the study if they have fulminant Crohn's disease requiring parenteral steroid treatment, hospitalization, or need of surgery imminently.
  • Patients with serious infections in the preceding three months, opportunistic infections within one month, or current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, endocrine, pulmonary, cardiac, neurological, or cerebral disease will be excluded.
  • Patients will also be excluded from the study if they have a history of a seizure, epilepsy, presumed current central nervous system tumor, have or have had anorexia nervosa or bulimia, are currently taking or have taken in the last four weeks any drug in the monoamine oxidase inhibitor class, or are allergic to Wellbutrin.
  • Patients with active major depression or suicidal ideation will be excluded, as will patients with a score of 19 or higher on the Beck depression inventory.
  • Patients will be excluded if they are currently or have taken a medicine in the selective serotonin reuptake class, mirtazapine, venlafaxine, a tricyclic antidepressant, a mood stabilizing, or antipsychotic medication in the previous two weeks.
  • Patients will be excluded if they are currently abusing alcohol or have alcohol dependence.
  • Patients will be excluded from the study if their baseline liver function tests are greater than twice the upper limit of normal, or if a clinical investigator believes that their baseline chemistry, liver function tests or complete blood count contraindicates entry into the study.
  • Pregnant or lactating females are excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00126373

United States, Illinois
University of Chicago
Chicago, Illinois, United States, 60637
United States, New York
Mt. Sinai Medical Center
New York, New York, United States, 10029
Sponsors and Collaborators
Altschuler, Eric, M.D.
Principal Investigator: Eric L Altschuler, M.D., Ph.D. Mt. Sinai Medical Center
  More Information

No publications provided

Responsible Party: Altschuler, Eric, M.D. Identifier: NCT00126373     History of Changes
Other Study ID Numbers: CGO10410022
Study First Received: August 2, 2005
Last Updated: January 19, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Altschuler, Eric, M.D.:
Crohn disease

Additional relevant MeSH terms:
Crohn Disease
Digestive System Diseases
Gastrointestinal Diseases
Inflammatory Bowel Diseases
Intestinal Diseases
Antidepressive Agents
Antidepressive Agents, Second-Generation
Central Nervous System Agents
Dopamine Agents
Dopamine Uptake Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses processed this record on February 27, 2015